Results 21 to 30 of about 9,412 (255)
Frontiers in Immunology, 2022 Mesalamine (MES), also known as 5-aminosalicylic acid, is effective in treating mild to moderate ulcerative colitis (UC). The mechanisms of its actions are not fully elucidated.
Yonggang Huang +4 more
semanticscholar +1 more source
Development and Optimization of RP-UHPLC Method for Mesalamine Through QbD Approach
Dhaka University Journal of Pharmaceutical Sciences, 2022 The current study aimed at developing and optimizing a prompt, simple and efficient RP-UHPLC method based on Quality by Design (QbD) for analyzing mesalamine.
Diponkor Kumar Shill +4 more
semanticscholar +1 more source
New German guidelines for the management of diverticulitis
, 2022 United European Gastroenterology Journal, Volume 10, Issue 9, Page 913-914, November 2022.
Anne F. Peery
wiley +1 more source
Successful management of HIV infection in a patient with ulcerative colitis; a case report [PDF]
Journal of Preventive Epidemiology, 2021 Human immunodeficiency virus (HIV) is an infectious disease that is rarely seen in ulcerative colitis patients. Both diseases commonly involve the colon.
Zain Majid +5 more
doaj +1 more source
Oxidative Medicine and Cellular Longevity, 2022 Objective To systematically assess effectiveness and safety of Bifidobacterium quadruple viable bacteria combined with mesalamine against ulcerative colitis (UC) in the Asian population.
Fei Xie +7 more
semanticscholar +1 more source
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study [PDF]
Intestinal Research, 2016 Background/AimsThe therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients.
Yasuo Suzuki +4 more
doaj +1 more source
Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
Journal of clinical biochemistry and nutrition, 2022 Mesalamine is a key drug in the treatment of ulcerative colitis (UC) for both induction and maintenance therapy. On the other hand, it is known that there are some cases of mesalamine intolerance that are difficult to distinguish from symptoms due to ...
Y. Minagawa +19 more
semanticscholar +1 more source
Medicina, 2022 A 41-year-old man was treated with prednisolone (PSL) and multimatrix (MMX) mesalamine for remission induction therapy of ulcerative colitis. PSL was tapered due to successful remission induction treatment.
Mimari Kanazawa +9 more
doaj +1 more source
Global Pediatric Health, 2022 Collagenous gastritis and collagenous colitis are 2 rare gastrointestinal disorders in pediatric patients. Both of these disease processes exist on a clinical spectrum, and are extremely rare to be present together in the pediatric population. Due to the
Ankit Mishra +3 more
semanticscholar +1 more source
Suppository treatment in ulcerative proctitis
European Journal of Inflammation, 2021 Ulcerative proctitis (UP) is a common form of ulcerative colitis (UC), the number of patients with UP is increasing. Suppository treatment containing mesalamine is usually the first-line choice for mild to moderate UP, here, we review the publications on
Yingjie Si +3 more
doaj +1 more source